Trial Profile
A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Cerebral atrophy
- Focus Adverse reactions
- 16 Dec 2012 New trial record